Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

INTRODUCTION: For most locally advanced non–small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended. Here, we explore causes and consequences of early durvalumab discontinuati...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennock, Michael, Halmos, Balazs, Bodner, William, Cheng, Haiying, Gucalp, Rasim, Ohri, Nitin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279777/
https://www.ncbi.nlm.nih.gov/pubmed/37346274
http://dx.doi.org/10.1016/j.ctro.2023.100643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279777/
https://www.ncbi.nlm.nih.gov/pubmed/37346274
http://dx.doi.org/10.1016/j.ctro.2023.100643

Ejemplares similares